ElastiMed

ElastiMed develops wearable active compression devices for people with lymphatic and venous conditions. Its product, MyoSleeve, is a low-profile garment worn under clothing that wraps around the calf and actively massages the lower leg, delivering therapeutic compression intended to mimic manual lymphatic drainage while the user remains mobile. The company describes the system as cable-free and silent, with a hook-and-loop fit and one-touch start, and states it can be worn for up to eight hours of uninterrupted treatment. Integrated sensors for tracking limb metrics and sharing data with a therapist are described as forthcoming.

The underlying technology uses electro-active polymers (EAPs), sometimes called artificial muscles: soft plastic films that stretch and contract in response to an electric pulse. ElastiMed developed a proprietary method for holding EAP film in a pre-stretched state and forming it into thin linear actuators, producing a strap that contracts when stimulated by a low-voltage source (a 3V battery in earlier descriptions). Wrapping several straps around the leg and activating them in sequence converts the contraction into rhythmic compression that mimics calf muscle contractions and stimulates blood flow. An earlier smart-stocking iteration of the product was branded ComFyt.

The company positions the device against the two prevailing options in compression therapy: compression stockings, which it says suffer from more than 60% non-compliance because of tight fit and difficulty donning and doffing, and pneumatic compression devices, which it characterizes as effective but expensive, noisy, heavy and limiting to mobility. Targeted indications include chronic leg swelling/edema, lymphedema, varicose veins, chronic venous insufficiency, venous ulcers and prevention of deep vein thrombosis, with stated potential extensions to sports recovery, travel- and desk-related swelling, chronic wounds, and arm and full-leg treatment.

Founding story

The company was founded in 2015 by Omer Zelka, an engineer with medical device leadership experience and a background in electro-active materials, who serves as CEO and a board member. He assembled a board of directors and a scientific advisory board including vascular and wound care physicians from the United States, Israel and Germany and a materials science academic.

Business model

ElastiMed develops and manufactures a wearable medical device for compression therapy. It has pursued distribution through partners, including an exclusive U.S. distribution agreement with Tactile Medical covering MyoSleeve for VA and Department of Defense patients. Its contact form segments inquiries by patient, VA patient, clinician and health plan (payer), indicating channels spanning clinicians, payers and government health systems. Development has been financed in part by non-dilutive grants from the Israel Innovation Authority and the EU Horizon 2020 SME Instrument.

Sales of the MyoSleeve compression device, with distribution via partners such as Tactile Medical and stated engagement with health plans/payers; The Trendlines Group classifies the company as being at the revenue stage.

Traction

An initial clinical study on 11 healthy subjects reported an average 141% increase in peak flow velocity after 30 minutes of use, described as comparable to standard pneumatic compression devices. A clinical study at Sheba Medical Center's rehabilitation departments compared the device on one leg against a medical compression bandage on the other, reporting more than four times better leg volume reduction than standard treatment across 12 legs tested at the time. The company reported one granted patent and four pending applications, inbound interest from thousands of patients, FDA clearance of its technology, and Trendlines lists it at the revenue stage.

Latest developments

Tactile Medical entered an exclusive U.S. distribution agreement with ElastiMed for the MyoSleeve wearable compression device serving VA and DoD patients. Dr. Amir Belson was named chairman of the board and Dr. Antonios Gasparis joined the medical advisory board. The company plans to exhibit at the VEITH Symposium 2026.